x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012170
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala419 of human IMPDH2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | IMPDH2 |
| UniProt No. | P12268 |
| Gene ID | 3615 |
| Gene Description | Inosine-5'-monophosphate dehydrogenase catalyzes the conversion of IMP to XMP, the first and rate-limiting step of guanine nucleotide biosynthesis. The isozymes IMPDH1 and IMPDH2 are encoded by two distinct genes. Research studies show that IMPDH2 is overexpressed in glioblastoma. In glioblastoma, IMPDH2-mediated GTP biosynthesis is essential for rRNA and tRNA synthesis and the formation of enlarged and irregular nucleoli. In addition, IMPDH1 and IMPDH2 double knockout leads to significant inhibition of tumor growth in an orthotopic glioblastoma model. Furthermore, IMPDH1 and IMPDH2 expression is upregulated in small cell lung cancer cells with low expression of ASCL1 transcription factor. Suppression of IMPDH activity inhibits ASCL1Low small cell lung cancer growth. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
